Zentiva Completes Voluntary Public Purchase Offer for APONTIS PHARMA AG

AptarGroup Acquires Majority Stake in Voluntis

September 2, 2021

Healthcare Services

AptarGroup, Inc. completed the acquisition of approximately 64.6% of the share capital of Voluntis (ENXTPA: ALVTX) at €8.70 per share from the company’s reference shareholders and certain management members. Aptar will launch a mandatory cash tender offer for the remaining shares at the same price, and has already appointed board representatives and a deputy CEO as it integrates Voluntis into its digital health capabilities.

Qvantel Acquires Optiva Inc.

December 31, 2025

Software

Qvantel Oy completed its acquisition of Optiva Inc. via a statutory plan of arrangement, acquiring all issued and outstanding common shares of Optiva. The transaction paid Optiva shareholders C$0.25 per common share, cancelled Optiva's US$108.6 million PIK notes with consideration to noteholders (including purchaser shares, purchaser-issued senior secured notes and warrants), and will result in Optiva being dissolved and delisted from the Toronto Stock Exchange. The combined company expands Qvantel's telecom monetization and digital operations portfolio and supports more than 70 operators with a global workforce exceeding 1,000 professionals.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva, Inc. agreed to acquire all outstanding shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis' equity at approximately $113 million on a fully diluted basis. The transaction makes Entasis a wholly owned subsidiary of Innoviva and advances Innoviva's strategy to expand into differentiated late-stage biopharmaceutical assets, including Entasis' lead antibacterial candidate SUL-DUR.

PAI Pharma Acquires Nivagen Pharmaceuticals

January 8, 2026

Pharmaceuticals

PAI Pharma, an Olympus Partners portfolio company, has acquired Nivagen Pharmaceuticals to add a newly built aseptic sterile-injectable manufacturing facility in Sacramento, California and a pipeline of more than 20 ready-to-use (RTU) injectable products. The add-on expands PAI's sterile injectable capabilities alongside its oral liquid franchise to better serve hospitals and health systems and strengthen U.S. pharmaceutical supply-chain resilience; financial terms were not disclosed.

Avesi Partners Invests in Visante

February 12, 2024

Healthcare Services

Avesi Partners has made a minority growth investment in Visante, a St. Paul–based provider of tech-enabled pharmacy consulting and services for health systems. The partnership will support Visante’s growth and capability expansion across specialty and infusion pharmacy markets and includes an internal leadership transition with Steve Rough named CEO and Jim Jorgenson moving to an advisory role.

Juvisé Pharmaceuticals Acquires Ponvory (ex-US/Canada) from Actelion; Bpifrance and Pemberton Invest in Juvisé

March 26, 2024

Pharmaceuticals

Juvisé Pharmaceuticals has acquired global commercial rights (excluding the United States and Canada) to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson company. To fund the transaction, French sovereign fund Bpifrance and private credit manager Pemberton Asset Management took minority stakes in Juvisé; Juvisé will commercialize and assume manufacturing duties for Ponvory in Europe.